Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Heron Therapeutics ( (HRTX) ) has provided an update.
Heron Therapeutics has appointed Michael Kaseta to its Board of Directors, bringing his extensive experience in corporate finance and biopharma commercialization to the company. Kaseta, currently the CFO and COO at Liquida Corporation, has a proven track record in financial leadership roles at various pharmaceutical firms. Heron’s CEO, Craig Collard, expressed confidence in Kaseta’s ability to contribute to the company’s growth, particularly in enhancing its portfolio of products aimed at improving patient care.
Find detailed analytics on HRTX stock on TipRanks’ Stock Analysis page.